HEME-20

Free From Maintenance Drug Therapy in Multiple Myeloma (The FREEDMM Trial) for Minimal Residual Disease (MRD) (HEME-20)

What's the purpose of the trial?

A pilot study to assess the risk of progression after stopping post-autologous stem cell transplant (ASCT) maintenance therapy in Minimal Residual Disease (MRD)-negative MM patients.

Trial status

Accepting patients

Phase
Pilot Trial
Enrollment
50
Last Updated
2 months ago
Patient Screener

Participating Centers

There is one center participating in this trial. Enter a location below to view the distance.

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Accepting patients

Bone Marrow Minimal Residual Disease Negative

Accepting patients

Bone Marrow Minimal Residual Disease Positive

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 850-0650

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.